{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:13:05Z","timestamp":1788833585391,"version":"build-2803163510"},"reference-count":94,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Androgen-deprivation therapy (ADT) is a systemic therapy administered for the management of advanced prostate cancer (PCa). Although ADT may improve survival, long-term use reduces bone mass density (BMD), posing an increased risk of fracture. Considering the long natural history of PCa, it is essential to preserve bone health and quality-of-life in patients on long-term ADT. As an alternative to pharmacological interventions targeted at preserving BMD, current evidence recommends lifestyle modifications, including individualized exercise and nutritional interventions. Exercise interventions include resistance training, aerobic exercise, and weight-bearing impact exercise, and have shown efficacy in preserving BMD. At the same time, it is important to take into account that PCa is a progressive and debilitating disease in which a substantial proportion of patients on long-term ADT are older individuals who harbor axial bone metastases. Smoking cessation and limited alcohol consumption are commonly recommended lifestyle measures in patients receiving ADT. Contemporary guidelines regarding lifestyle modifications vary by country, organization, and expert opinion. This comprehensive review will provide an evidence-based, updated summary of lifestyle interventions that could be implemented to preserve bone health and maintain quality-of-life throughout the disease course of PCa.<\/jats:p>","DOI":"10.3390\/cancers12061529","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T12:16:57Z","timestamp":1592223417000},"page":"1529","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7836-1998","authenticated-orcid":false,"given":"Tae Jin","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Urology, CHA Bundang Medical Center, CHA University College of Medicine, Seongnam 13496, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7303-6256","authenticated-orcid":false,"given":"Kyo Chul","family":"Koo","sequence":"additional","affiliation":[{"name":"Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06229, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.prnil.2015.02.006","article-title":"Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels","volume":"3","author":"Koo","year":"2015","journal-title":"Prostate Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11934-010-0103-y","article-title":"The Quality-of-Life Impact of Prostate Cancer Treatments","volume":"11","author":"Singh","year":"2010","journal-title":"Curr. Urol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2015.04.023","article-title":"Survivorship and Improving Quality of Life in Men with Prostate Cancer","volume":"68","author":"Bourke","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kim, D.K., Lee, J.Y., Kim, K.J., Hong, N., Kim, J.W., Hah, Y.S., Koo, K.C., Kim, J.H., and Cho, K.S. (2019). Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis. J. Clin. Med., 8.","DOI":"10.3390\/jcm8010113"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5489\/cuaj.117","article-title":"Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice","volume":"6","author":"So","year":"2012","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"New Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/pcan.2016.62","article-title":"Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: Data from PREVAIL and AFFIRM trials","volume":"20","author":"Saad","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.02.002","article-title":"Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer","volume":"44","author":"Vignani","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1158\/1078-0432.CCR-06-0269","article-title":"Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer","volume":"12","author":"Cook","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of Bone Metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/0008-5472.CAN-14-2493","article-title":"Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases","volume":"75","author":"Sottnik","year":"2015","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00223-017-0350-8","article-title":"Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis","volume":"102","author":"Park","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1152\/physrev.00033.2015","article-title":"Estrogens and Androgens in Skeletal Physiology and Pathophysiology","volume":"97","author":"Almeida","year":"2017","journal-title":"Physiol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2147\/CIA.S115472","article-title":"A concise review of testosterone and bone health","volume":"11","author":"Mohamad","year":"2016","journal-title":"Clin. Interv. Aging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1210\/er.2014-1024","article-title":"Sex steroid actions in male bone","volume":"35","author":"Vanderschueren","year":"2014","journal-title":"Endocr. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.mce.2018.10.008","article-title":"The androgen receptor is required for maintenance of bone mass in adult male mice","volume":"479","author":"Wu","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.steroids.2008.10.003","article-title":"Androgens and bone","volume":"74","author":"Clarke","year":"2008","journal-title":"Steroids"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1359\/jbmr.1997.12.3.464","article-title":"Gonadal and Adrenal Androgens Are Potent Regulators of Human Bone Cell Metabolism In Vitro","volume":"12","author":"Kasperk","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/jbmr.2529","article-title":"New Insights Into Androgen and Estrogen Receptor Regulation of the Male Skeleton","volume":"30","author":"Khosla","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_23","first-page":"1","article-title":"Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies","volume":"2015","author":"Stenzl","year":"2015","journal-title":"Int. J. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1210\/jc.2013-3233","article-title":"Association Between Sex Steroid Levels and Bone Microarchitecture in Men: The STRAMBO Study","volume":"99","author":"Argoud","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ecl.2012.05.001","article-title":"Male osteoporosis","volume":"41","author":"Drake","year":"2012","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/jbmr.3746","article-title":"Relationship Between Sex Steroids and Deterioration of Bone Microarchitecture in Older Men: The Prospective STRAMBO Study","volume":"34","author":"Piot","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","article-title":"Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer","volume":"57","author":"Kiratli","year":"2001","journal-title":"Urology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11926-011-0173-y","article-title":"Advances in Glucocorticoid-Induced Osteoporosis","volume":"13","author":"Uyl","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_29","first-page":"1231","article-title":"Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer","volume":"19","author":"Auchus","year":"2014","journal-title":"Oncology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/annonc\/mds216","article-title":"Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer","volume":"24","author":"Dorff","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.critrevonc.2017.09.008","article-title":"The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials","volume":"120","author":"Rizzo","year":"2017","journal-title":"Crit. Rev. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","article-title":"Enzalutamide monotherapy in hormone-naive prostate cancer: Primary analysis of an open-label, single-arm, phase 2 study","volume":"15","author":"Tombal","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","article-title":"Bicalutamide Monotherapy Versus Leuprolide Monotherapy for Prostate Cancer: Effects on Bone Mineral Density and Body Composition","volume":"22","author":"Smith","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12520","DOI":"10.18632\/oncotarget.3724","article-title":"Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment","volume":"6","author":"Iuliani","year":"2015","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/mend.12.7.0136","article-title":"Progression of LNCaP Prostate Tumor Cells during Androgen Deprivation: Hormone-Independent Growth, Repression of Proliferation by Androgen, and Role for p27Kip1 in Androgen-Induced Cell Cycle Arrest","volume":"12","author":"Kokontis","year":"1998","journal-title":"Mol. Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"269ra2","DOI":"10.1126\/scitranslmed.3010563","article-title":"Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study","volume":"7","author":"Schweizer","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/pros.21196","article-title":"Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen\/ablation in men with castration resistant prostate cancer","volume":"70","author":"Denmeade","year":"2010","journal-title":"Prostate"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/pros.23209","article-title":"Bipolar Androgen Therapy for Men With Androgen Ablation Na\u00efve Prostate Cancer: Results From the Phase II BATMAN Study","volume":"76","author":"Schweizer","year":"2016","journal-title":"Prostate"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.juro.2011.03.111","article-title":"Factors Associated With Vertebral Fractures in Men Treated With Androgen Deprivation Therapy for Prostate Cancer","volume":"186","author":"Saylor","year":"2011","journal-title":"J. Urol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.2047-2927.2013.00093.x","article-title":"Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: Implementation of standardized management guidelines","volume":"1","author":"Cheung","year":"2013","journal-title":"Andrology"},{"key":"ref_42","first-page":"109","article-title":"Bisphosphonates: Prevention of Bone Metastases in Prostate Cancer","volume":"192","author":"Saad","year":"2012","journal-title":"Adv. Struct. Saf. Stud."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrendo.2013.171","article-title":"Osteoporosis in men","volume":"9","author":"Walsh","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrrheum.2015.48","article-title":"A look behind the scenes: The risk and pathogenesis of primary osteoporosis","volume":"11","author":"Hendrickx","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2605.2000.00001.x","article-title":"Hormonal deficiency in elderly males","volume":"23","author":"Qian","year":"2000","journal-title":"Int. J. Androl."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.bone.2012.11.006","article-title":"Clinical risk factors, bone density and fall history in the prediction of incident fracture among men and women","volume":"52","author":"Edwards","year":"2012","journal-title":"Bone"},{"key":"ref_47","first-page":"99","article-title":"Managing Bone Loss and Bone Metastases in Prostate Cancer Patients: A Focus on Bisphosphonate Therapy","volume":"10","author":"Israeli","year":"2008","journal-title":"Rev. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jcb.10662","article-title":"Prostate cancer bone metastases promote both osteolytic and osteoblastic activity","volume":"91","author":"Keller","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jocd.2019.07.006","article-title":"Dual-energy X-ray Absorptiometry Monitoring with Trabecular Bone Score: 2019 ISCD Official Position","volume":"22","author":"Krohn","year":"2019","journal-title":"J. Clin. Densitom."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","article-title":"Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women","volume":"286","author":"Siris","year":"2001","journal-title":"JAMA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.medcli.2013.06.008","article-title":"La herramienta FRAX\u00ae en la prevenci\u00f3n de fracturas asociadas al tratamiento de privaci\u00f3n androg\u00e9nica en el c\u00e1ncer de pr\u00f3stata","volume":"142","author":"Azagra","year":"2013","journal-title":"Med. Cl\u00ednica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e000652","DOI":"10.1136\/esmoopen-2019-000652","article-title":"Bone health management in the continuum of prostate cancer disease: A review of the evidence with an expert panel opinion","volume":"5","author":"Santini","year":"2020","journal-title":"ESMO Open"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"d3651","DOI":"10.1136\/bmj.d3651","article-title":"Predicting risk of osteoporotic and hip fracture in the United Kingdom: Prospective independent and external validation of QFractureScores","volume":"342","author":"Collins","year":"2011","journal-title":"BMJ"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e005809","DOI":"10.1136\/bmjopen-2014-005809","article-title":"The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: A validation study","volume":"4","author":"Coupland","year":"2014","journal-title":"BMJ Open"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.bone.2007.11.018","article-title":"Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: Applications in the study of human trabecular bone microarchitecture","volume":"42","author":"Pothuaud","year":"2008","journal-title":"Bone"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jbo.2016.10.004","article-title":"Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score","volume":"7","author":"Mariotti","year":"2016","journal-title":"J. Bone Oncol."},{"key":"ref_59","first-page":"501","article-title":"Gu\u00eda de la EAU sobre el c\u00e1ncer de pr\u00f3stata. Parte I: Cribado, diagn\u00f3stico y tratamiento del c\u00e1ncer cl\u00ednicamente localizado","volume":"35","author":"Heidenreich","year":"2011","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas"},{"key":"ref_60","first-page":"583","article-title":"NCCN Guidelines Updates: Management of Prostate Cancer","volume":"17","author":"Mohler","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1053\/j.semnuclmed.2014.06.006","article-title":"Osteoporosis","volume":"44","author":"Nanes","year":"2014","journal-title":"Semin. Nucl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/cncr.21047","article-title":"Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy","volume":"103","author":"Agarwal","year":"2005","journal-title":"Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5694\/j.1326-5377.2011.tb02979.x","article-title":"Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy","volume":"194","author":"Grossmann","year":"2011","journal-title":"Med. J. Aust."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.3747\/co.v18i4.746","article-title":"A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy","volume":"18","author":"Lee","year":"2011","journal-title":"Curr. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/pcan.2016.69","article-title":"Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: An update","volume":"20","author":"Owen","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Saylor, P.J., Rumble, R.B., and Michalski, J.M. (2020). Bone Health and Bone-Targeted Therapies for Prostate Cancer: American Society of Clinical Oncology Endorsement Summary of a Cancer Care Ontario Guideline. JCO Oncol. Pr.","DOI":"10.1200\/JOP.19.00778"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1557988315615956","article-title":"Osteoporosis-Related Health Behaviors in Men With Prostate Cancer and Survivors","volume":"11","author":"Lassemillante","year":"2016","journal-title":"Am. J. Men\u2019s Health"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jneb.2007.08.009","article-title":"Are Cancer Survivors\/Patients Knowledgeable About Osteoporosis? Results from a Survey of 285 Chemotherapy-treated Cancer Patients and Their Companions","volume":"40","author":"Mckean","year":"2008","journal-title":"J. Nutr. Educ. Behav."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1464-410X.2012.11777.x","article-title":"Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer","volume":"111","author":"Nadler","year":"2013","journal-title":"BJU Int."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00520-014-2127-1","article-title":"Awareness, concern, and communication between physicians and patients on bone health in cancer","volume":"22","author":"Tripathy","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2006.01.054","article-title":"Prevention and management of osteoporosis in men receiving androgen deprivation therapy: A survey of urologists and radiation oncologists","volume":"68","author":"Alibhai","year":"2006","journal-title":"Urology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00198-014-2997-6","article-title":"Bone health management in men undergoing ADT: Examining enablers and barriers to care","volume":"26","author":"Damji","year":"2014","journal-title":"Osteoporos. Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/cncr.31171","article-title":"Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial","volume":"124","author":"Alibhai","year":"2017","journal-title":"Cancer"},{"key":"ref_74","first-page":"1","article-title":"Online Educational Tool to Promote Bone Health in Cancer Survivors","volume":"22","author":"Bordes","year":"2017","journal-title":"J. Health Commun."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Batai, K., Murphy, A.B., Ruden, M., Newsome, J., Shah, E., Dixon, M.A., Jacobs, E.T., Hollowell, C.M.P., Ahaghotu, C., and Kittles, R.A. (2017). Race and BMI modify associations of calcium and vitamin D intake with prostate cancer. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3060-8"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41585-018-0015-z","article-title":"Do dietary calcium and vitamin D matter in men with prostate cancer?","volume":"15","author":"Capiod","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_77","first-page":"1171","article-title":"Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review","volume":"17","author":"Datta","year":"2012","journal-title":"Oncology"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Nelson, S.M., Batai, K., Ahaghotu, C., Agurs-Collins, T., and Kittles, R.A. (2016). Association between Serum 25-Hydroxy-Vitamin D and Aggressive Prostate Cancer in African American Men. Nutrients, 9.","DOI":"10.3390\/nu9010012"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11606-009-0968-y","article-title":"Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy","volume":"24","author":"Saylor","year":"2009","journal-title":"J. Gen. Intern. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"686","DOI":"10.5694\/mja11.10301","article-title":"Vitamin D and health in adults in Australia and New Zealand: A position statement","volume":"196","author":"Nowson","year":"2012","journal-title":"Med. J. Aust."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3945\/ajcn.113.067157","article-title":"Dairy products, calcium, and prostate cancer risk: A systematic review and meta-analysis of cohort studies","volume":"101","author":"Aune","year":"2014","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1210\/jc.2012-1451","article-title":"Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance","volume":"97","author":"Marshall","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00223-019-00586-1","article-title":"Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?","volume":"105","author":"Owen","year":"2019","journal-title":"Calcif. Tissue Int."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.beem.2013.05.001","article-title":"Androgens and prostate cancer; pathogenesis and deprivation therapy","volume":"27","author":"Grossmann","year":"2013","journal-title":"Best Pr. Res. Clin. Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos. Int."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/2672435","article-title":"Exercise and Protein Intake: A Synergistic Approach against Sarcopenia","volume":"2017","author":"Martone","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1249\/01.mss.0000233803.48691.8b","article-title":"Resistance Training and Reduction of Treatment Side Effects in Prostate Cancer Patients","volume":"38","author":"Nosaka","year":"2006","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/0284186X.2015.1037008","article-title":"Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy","volume":"54","author":"Nilsen","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bju.12646","article-title":"Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: A randomised controlled trial","volume":"115","author":"Cormie","year":"2014","journal-title":"BJU Int."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1249\/MSS.0000000000000265","article-title":"Skeletal Response to Resistance and Impact Training in Prostate Cancer Survivors","volume":"46","author":"Dobek","year":"2014","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00198-015-3399-0","article-title":"Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial","volume":"27","author":"Uth","year":"2015","journal-title":"Osteoporos. Int."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00198-008-0776-y","article-title":"Effects of a multi-component exercise program and calcium\u2013vitamin-D3-fortified milk on bone mineral density in older men: A randomised controlled trial","volume":"20","author":"Kukuljan","year":"2008","journal-title":"Osteoporos. Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s11357-011-9311-8","article-title":"Exercise effects on bone mineral density in older adults: A meta-analysis of randomized controlled trials","volume":"34","author":"Marques","year":"2011","journal-title":"AGE"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5993\/AJHB.44.1.10","article-title":"Impact of Lifestyle Intervention for Patients with Prostate Cancer","volume":"44","author":"Park","year":"2020","journal-title":"Am. J. Health Behav."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1529\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:37:35Z","timestamp":1760175455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":94,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cancers12061529"],"URL":"https:\/\/doi.org\/10.3390\/cancers12061529","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]}}}